442 related articles for article (PubMed ID: 19251818)
61. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
Kalgutkar AS; Choo E; Taylor TJ; Marfat A
Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
[TBL] [Abstract][Full Text] [Related]
62. A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.
Olsen GW; Chang SC; Noker PE; Gorman GS; Ehresman DJ; Lieder PH; Butenhoff JL
Toxicology; 2009 Feb; 256(1-2):65-74. PubMed ID: 19059455
[TBL] [Abstract][Full Text] [Related]
63. Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells.
Sbaraglini ML; Molinuevo MS; Sedlinsky C; Schurman L; McCarthy AD
Eur J Pharmacol; 2014 Mar; 727():8-14. PubMed ID: 24485890
[TBL] [Abstract][Full Text] [Related]
64. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
[TBL] [Abstract][Full Text] [Related]
65. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
66. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.
Iwatsubo T; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):462-9. PubMed ID: 9353358
[TBL] [Abstract][Full Text] [Related]
67. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.
Jost MM; Lamerz J; Tammen H; Menzel C; De Meester I; Lambeir AM; Augustyns K; Scharpé S; Zucht HD; Rose H; Jürgens M; Schulz-Knappe P; Budde P
Biochem Pharmacol; 2009 Jan; 77(2):228-37. PubMed ID: 18940185
[TBL] [Abstract][Full Text] [Related]
68. A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Zhang L; Boulton DW; Pfister M
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):126S-33S. PubMed ID: 22232748
[TBL] [Abstract][Full Text] [Related]
69. Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats.
Ikeda J; Kimoto N; Kitayama T; Kunori S
J Pharmacol Sci; 2016 Sep; 132(1):65-70. PubMed ID: 27666017
[TBL] [Abstract][Full Text] [Related]
70. Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer.
Beconi M; Mao A; Creighton M; Hop CE; Chiu SH; Eydelloth R; Franklin R; Tang F; Yu N; Vincent S
Xenobiotica; 2003 Jul; 33(7):767-87. PubMed ID: 12893525
[TBL] [Abstract][Full Text] [Related]
71. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.
Germann N; Urien S; Rodgers AH; Ratterree M; Struck RF; Waud WR; Serota DG; Bastian G; Jursic BS; Morgan LR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):143-51. PubMed ID: 15592722
[TBL] [Abstract][Full Text] [Related]
72. Stereoselective metabolism of tazofelone, an anti-inflammatory bowel disease agent, in rats and dogs and in human liver microsomes.
Clay MP; Hanssen BR; Surapaneni SS; Lindstrom TD
Chirality; 1999; 11(3):233-40. PubMed ID: 10079502
[TBL] [Abstract][Full Text] [Related]
73. Distribution and metabolism of prednisone in mice, dogs, and monkeys.
El Dareer SM; Struck RF; White VM; Mellett LB; Hill DL
Cancer Treat Rep; 1977 Oct; 61(7):1279-89. PubMed ID: 412589
[TBL] [Abstract][Full Text] [Related]
74. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
Shibayama T; Matsushita Y; Kawai K; Hirota T; Ikeda T; Kuwahara S
Antimicrob Agents Chemother; 2007 Jan; 51(1):257-63. PubMed ID: 17074792
[TBL] [Abstract][Full Text] [Related]
76. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
[TBL] [Abstract][Full Text] [Related]
77. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.
Attkins N; Betts A; Hepworth D; Heatherington AC
Xenobiotica; 2010 Nov; 40(11):730-42. PubMed ID: 20836725
[TBL] [Abstract][Full Text] [Related]
78. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
79. Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423--a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity.
Smrdel P; Grabnar I; Locatelli I; Cerne M; Andrensek S; Kovacic N; Kristl A; Bogataj M; Urleb U; Mrhar A
Drug Dev Ind Pharm; 2009 Nov; 35(11):1293-304. PubMed ID: 19832629
[TBL] [Abstract][Full Text] [Related]
80. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
